1
|
Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer 2011; 106:85-91. [PMID: 22127285 PMCID: PMC3251861 DOI: 10.1038/bjc.2011.514] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background: Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma. Methods: Patients had ECOG performance status 0–2 and normal organ function. Dacarbazine was administered on day 1 and dasatinib on day 2 through 19 of each 21-day cycle. Both were escalated from 50 mg b.i.d. of dasatinib and 800 mg m−2 of dacarbazine. Available pre-treatment biopsies were sequenced for BRAF, NRAS, and C-Kit mutations. Results: Dose-limiting toxicity was reached at dasatinib 70 mg b.i.d./dacarbazine 1000 mg m−2, and was predominantly haematological. In 29 patients receiving dasatinib 70 mg b.i.d., the objective response rate (ORR) was 13.8%, the clinical benefit rate (ORR+SD) was 72.4%, the 6-month progression-free survival (PFS) was 20.7%, and the 12-month overall survival (OS) was 34.5%. Two out of three patients who were wild type for BRAF, NRAS, and c-KIT mutations had confirmed partial responses, and one had a minor response. Conclusion: The recommended phase II dose is dasatinib70 mg b.i.d with dacarbazine 800 mg m−2. PFS and OS data for dasatinib at 70 mg b.i.d. with dacarbazine compared favourably with historical controls. Preliminary data support evaluating tumour mutation status further as a biomarker of response.
Collapse
Affiliation(s)
- A P Algazi
- University of California, San Francisco, MTZ-A741, 1600 Divisadero Street, San Francisco, CA 94143, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer 2010; 103:1548-53. [PMID: 20924376 PMCID: PMC2990578 DOI: 10.1038/sj.bjc.6605931] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2010] [Revised: 09/01/2010] [Accepted: 09/03/2010] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Sagopilone is a novel fully synthetic epothilone with promising preclinical activity and a favourable toxicity profile in phase I testing. METHODS A phase II pharmacokinetic and efficacy trial was conducted in patients with metastatic melanoma. Patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate haematological, and organ function, with up to 2 previous chemotherapy and any previous immunotherapy regimens. Sagopilone, 16 mg m⁻², was administered intravenously over 3 h every 21 days until progression or unacceptable toxicity. RESULTS Thirty-five patients were treated. Sagopilone showed multi-exponential kinetics with a mean terminal half-life of 64 h and a volume of distribution of 4361 l m⁻² indicating extensive tissue/tubulin binding. Only grade 2 or lower toxicity was observed: these included sensory neuropathy (66%), leukopenia (46%), fatigue (34%), and neutropenia (31%). The objective response rate was 11.4% (one confirmed complete response, two confirmed partial responses, and one unconfirmed partial response). Stable disease for at least 12 weeks was seen in an additional eight patients (clinical benefit rate 36.4%). CONCLUSION Sagopilone was well tolerated with mild haematological toxicity and sensory neuropathy. Unlike other epothilones, it shows activity against melanoma even in pretreated patients. Further clinical testing is warranted.
Collapse
Affiliation(s)
- R C DeConti
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
| | - A P Algazi
- University of California, San Francisco, MTZ-A741, 1600 Divisadero Street, San Francisco, CA 94143, USA
| | - S Andrews
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
| | - P Urbas
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
| | - O Born
- Drug Metabolism and Pharmacokinetics – Bioanalytics, Bayer Schering Pharma AG, Müllerstr, Berlin, Germany
| | - D Stoeckigt
- Drug Metabolism and Pharmacokinetics – Bioanalytics, Bayer Schering Pharma AG, Müllerstr, Berlin, Germany
| | - L Floren
- Drug Metabolism and Pharmacokinetics – Bioanalytics, Bayer Schering Pharma AG, Müllerstr, Berlin, Germany
| | - J Hwang
- University of California, San Francisco, MTZ-A741, 1600 Divisadero Street, San Francisco, CA 94143, USA
| | - J Weber
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
| | - V K Sondak
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
| | - A I Daud
- University of California, San Francisco, MTZ-A741, 1600 Divisadero Street, San Francisco, CA 94143, USA
| |
Collapse
|
3
|
Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 2010; 67:657-66. [PMID: 20509027 PMCID: PMC3043235 DOI: 10.1007/s00280-010-1326-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2010] [Accepted: 04/01/2010] [Indexed: 11/27/2022]
Abstract
Purpose High-dose pegylated interferon α-2b (peginterferon α-2b) significantly decreased disease recurrence in patients with resected stage III melanoma in a clinical study. We investigated the pharmacokinetics (PK) and safety of high-dose peginterferon α-2b in patients with high-risk melanoma. Methods For PK analysis, 32 patients received peginterferon α-2b 6 μg/(kg week) subcutaneously for 8 weeks (induction) then 3 μg/(kg week) for 4 weeks (maintenance). PK profiles were determined at weeks 1, 8, and 12. Exposure–response relationships between peginterferon α-2b and absolute neutrophil count (ANC) and alanine aminotransferase (ALT) level were also studied. Results Peginterferon α-2b was well-absorbed following SC administration, with a median Tmax of 24 h. Mean half-life estimates ranged from 43 to 51 h. The accumulation factor was 1.69 after induction therapy. PK parameters showed moderate interpatient variability. PK profiles were described by a one-compartmental model with first-order absorption and first-order elimination. Toxicity was profiled and was acceptable; observed side effects were similar to those previously described. Dose reduction produced proportional decreases in exposure and predictable effects on ANC in an Imax model; however, a PK/pharmacodynamic (PK/PD) relationship between peginterferon α-2b and ALT could not be established with high precision. Conclusions Peginterferon α-2b was well-absorbed and sustained exposure to peginterferon α-2b was achieved with the doses tested. These data confirm and extend previous PK observations of peginterferon α-2b in melanoma and solid tumors. Our PK/PD model of exposure and ANC effect provides useful information for prediction of peginterferon α-2b-related hematologic toxicity. Electronic supplementary material The online version of this article (doi:10.1007/s00280-010-1326-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- A I Daud
- Division of Hematology/Oncology, University of California, San Francisco, San Francisco, CA, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Algazi AP, Weber JS, Andrews S, Urbas P, Arimura E, Hwang J, Sondak VK, Bastian B, Daud A. A phase I/II trial of DTIC and dasatinib in metastatic melanoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8532] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Weber JS, Sarnaik A, Targan S, Yu B, Morelli D, Urbas P, Maker N, Yellin M, Nichol G. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9023] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9023 Background: Ipilimumab is a human anti-CTLA-4 antibody shown to have clinical activity in melanoma that is associated with immune-related adverse events (IrAEs). Methods: 50 HLA A*0201 positive patients with resected stages IIIC/IV melanoma received MART-1/gp100/tyrosinase peptides with adjuvant Montanide ISA 51 12 times subcutaneously with Ipilimumab at 3 or 10 mg/kg intravenously every 8 weeks for 12 months, and 25 HLA A *0201 negative patients received Ipilimumab alone at 10 mg/kg. Primary endpoints were toxicity and the achievement of a 40% rate of tolerable IrAEs. Immune responses measured by ELISPOT and tetramer assays, and time to relapse were also assessed. 3 melanoma peptides were administered at 1000 mcg/dose each. Results: Median age was 58, with 44 men and 31 women. 46 patients had stage IV, and 29 had stage IIIC resected disease. 19/75 (25%) patients had grades 3–4 IrAEs that were dose-limiting. No patient with dose limiting toxicity required hospitalization and all returned to baseline status with the use of systemic steroids. Assays of induction of IL-17 secreting T cells showed a positive association with freedom from relapse (p=0.049). Change in slope of the increase in total lymphocyte count at four weeks was also associated with a trend toward freedom from relapse and development of an IrAE. 27 of 75 patients have relapsed with a median of 23 months of follow-up. 10 were again rendered NED surgically and are alive without disease. 68 patients are alive, 10 with disease. Only 1/19 patients with grade 3/4 IrAE has died of disease, compared to 6/56 without a dose limiting IBE. 23 of 27 relapses occurred without a grade 3/4 IrAE, compared with 15 IrAEs in 48 patients without a relapse. ELISPOT assays showed that patients at 10 mg/kg actually had decreased responsiveness in fresh PBMC to PHA and the CEF (CMV, EBV, FLU) pool of peptides. Conclusions: IrAEs are associated with clinical benefit in patients with resected high-risk melanoma receiving Ipilimumab with or without a peptide vaccine. Increases in IL-17 secreting CD4 T cells and the slope of increase in total lymphocytes over 4 weeks are associated with freedom from relapse. These data support testing the current regimen at 10 mg/kg in a larger randomized trial. [Table: see text]
Collapse
Affiliation(s)
- J. S. Weber
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| | - A. Sarnaik
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| | - S. Targan
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| | - B. Yu
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| | - D. Morelli
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| | - P. Urbas
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| | - N. Maker
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| | - M. Yellin
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| | - G. Nichol
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Cedars-Sinai Medical Center, Los Angeles, CA; Medarex, Inc., Bloomsburg, NJ
| |
Collapse
|
6
|
Daud A, Weber J, Urbas P, Andrews S, Maker N, Sondak VK, DeConti RC. Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9031 Background: Sagopilone (ZK-Epothilone) is a novel, fully synthetic epothilone with promising preclinical activity in several cancer models. This phase II study aims to define the efficacy and safety of sagopilone in patients with metastatic melanoma, as well as perform pharmacokinetic evaluation of this dose and schedule. Methods: Patients with unresectable stage III or IV malignant melanoma, with up to 2 prior chemotherapy and any prior immunotherapy regimens with measurable disease were eligible. Sagopilone was administered at 16 mg/m2 as a 3-hour IV infusion every 21 days. The primary end point of the trial was response rate, and secondary endpoints included time to progression, overall survival, and tolerability. Pharmacokinetic analysis was done on the first 10 patients. A total of 37 patients were to be accrued to have 33 evaluable patients. The trial had a 0.90 power and assumed α of 0.03. Results: Thirty four patients have been enrolled to date. Sagopilone appears to be well tolerated: The most common side effects seen have been sensory neuropathy, (55%, 19/34, 5 Grade 2, 14Grade 1) motor neuropathy (23%, 8/34, All Grade 1); anemia (26 %, 9/34) neutropenia (14%, 5/34 1 Grade 2, 4 Grade 1) thrombocytopenia (14%, 5/34) and fatigue (38%, 13/34). Two patients have shown grade 3 events (syncope and mental status changes, respectively, possibly related to therapy), both of which resolved and an additional patient had a pulmonary embolism which was considered unlikely to be related to therapy. Responses have been seen in 4 patients (3 RECIST confirmed PR, 1 unconfirmed PR). Stable disease was seen for at least 12 weeks in an additional 10 patients for a clinical benefit rate (CR+PR+SD) of 44%. No grade 4 events have been reported. Conclusions: Unlike the epothilone analogs patupilone or ixabepilone, sagopilone appears to be an active drug in advanced melanoma. The side effect profile seen to date at 16 mg/m2 given over 3 hours repeated every 3 weeks appears to be notably free of myelosuppression indicating that it could be combined with other drugs active in melanoma. Pharmacokinetic studies show a prolonged terminal half life, probably due to release from deep tissue compartments. [Table: see text]
Collapse
Affiliation(s)
- A. Daud
- University of California, San Francisco, San Francisco, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - J. Weber
- University of California, San Francisco, San Francisco, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - P. Urbas
- University of California, San Francisco, San Francisco, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - S. Andrews
- University of California, San Francisco, San Francisco, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - N. Maker
- University of California, San Francisco, San Francisco, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - V. K. Sondak
- University of California, San Francisco, San Francisco, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| | - R. C. DeConti
- University of California, San Francisco, San Francisco, CA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
| |
Collapse
|
7
|
Wenk D, DeConti RC, Urbas P, Andrews S, Sondak VK, Maker N, Weber JS, Daud AI. Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9046] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|